Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

• Status: Terminated
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to learn about a new potential use for topical timolol 0.5% aqueous solution that may help treat small uncomplicated infantile hemangiomas. This study would examine whether topical timolol could be a potential therapy.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Treatments: Timolol

Criteria

Inclusion Criteria:

Infants 1 month to 8 months of age with infantile hemangioma (IH) that are 3 cm or less on the scalp, trunk, or extremities.

Exclusion Criteria:

1. Subjects with facial, genital, perianal, hand, finger, feet, or toe IH

2. Subjects with PHACES (plaque-like hemangioma on the face awaiting imaging) syndrome (proven) or suspected PHACES .

3. Subjects with IH measuring more than 3cm in size or ulcerated.

4. Children with a history of hypersensitivity to beta blockers.

5. Children with a personal history of asthma.

6. Children with known renal impairment.

7. Children with known cardiac conditions that may predispose to heart block

8. Personal history of hypoglycemia

9. Children on medications that may interact with beta blockers